Haleon plc (HLNCF)
| Market Cap | 41.41B |
| Revenue (ttm) | 15.07B |
| Net Income (ttm) | 1.62B |
| Shares Out | n/a |
| EPS (ttm) | 0.18 |
| PE Ratio | 25.58 |
| Forward PE | n/a |
| Dividend | 0.03 (0.56%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 3,018 |
| Average Volume | 192,653 |
| Open | 4.570 |
| Previous Close | 4.535 |
| Day's Range | 4.570 - 4.570 |
| 52-Week Range | 3.900 - 5.360 |
| Beta | 0.24 |
| RSI | 48.81 |
| Earnings Date | Feb 27, 2025 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops,... [Read more]
Full Company ProfileFinancial Performance
In 2023, Haleon's revenue was 11.30 billion, an increase of 4.09% compared to the previous year's 10.86 billion. Earnings were 1.05 billion, a decrease of -1.04%.
Financial numbers in GBP Financial StatementsNews
Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%
Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%
Pfizer Sells Stake in Haleon for $3.05 Billion
Pfizer Sells Stake in Haleon for $3.05 Billion
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
Pfizer to cut Haleon stake in 700M share sale
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
Haleon pioneers new era in pain management education at DUPHAT 2025
Haleon unveils new initiative at DUPHAT 2025, offering sophisticated pain management solutions with research and training for healthcare professionals
TUMS Teams Up with DraftKings to Launch TUMS Fantasy Foodball Pool, Making Gameday Food Dreams a Reality
Fans can draft their top food and drink picks for a free shot at winning a share of $40,000 in total cash prizes WARREN, N.J. , Jan. 9, 2025 /PRNewswire/ -- As hundreds of millions prepare to tune in...
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer Inc. (NYSE: PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance . Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commen...
Haleon Pakistan to manufacture Centrum multivitamins
Haleon Pakistan plans to start manufacturing multivitamin brand Centrum in the country for domestic sales and export, its CEO said, as it seeks to boost sales in the country amid lower inflation.
Haleon: Guidance Implies Uncertainty Around Flu Season
Leading Consumer Health Transformation With Purpose at Haleon
In this compelling episode of the Brave Commerce podcast, co-hosts Rachel Tipograph and Sarah Hofstetter sit down with Katie Williams, chief marketing officer of Haleon, parent company of consumer hea...
Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation
WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US busines...
Haleon Partners with WPP to Launch ‘HealthNxt’ initiative to Transform Health Conversations in India
Through the commitment of #HealthInMoreHands, Haleon aims to democratize healthcare in India, empowering individuals to take control of their health. NEW DELHI, Nov. 20, 2024 /PRNewswire/ — Haleon (fo...
Dividend Income: Lanny's October 2024 Summary
Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, s...
Eminence Capital buys Gitlab, Charles River, exits Haleon, others in Q3
Eminence Capital added new positions in Gitlab, Charles River, Okta, and Atmus Filtration while exiting stakes in Haleon, Wix.com, Prologis, and GoDaddy in...
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising
Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon CEO Brian McNamara: We've seen double-digit growth in China
Haleon CEO Brian McNamara joins 'Mad Money' host Jim Cramer to talk quarterly results, China growth, consumer trends and more.
Revenues fall at Sensodyne maker Haleon after weaker painkiller sales
Shares were lower in early trading on Thursday as a result.
Haleon reports marginal decline in third-quarter revenue
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
Is the Haleon share price in trouble ahead of earnings?
Haleon (HLN) share price has retreated in the past few weeks, erasing some of the gains made earlier this year. Its London stock dropped to 375p, its lowest point since August 29, while its American A...
Haleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted Out
Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock and why I recommend a sell rating.